Not Found
Locations

Find information on medical topics, symptoms, drugs, procedures, news and more, written for the health care professional.

* This is the Professional Version. *

Protein S Deficiency

By Joel L. Moake, MD, Rice University;Baylor College of Medicine

Click here for
Patient Education

Because protein S binds and assists activated protein C in the degradation of coagulation factors Va and VIIIa, deficiency of protein S predisposes to venous thrombosis.

Protein S, a vitamin K–dependent protein, is a cofactor for activated protein C–mediated cleavage of factors Va and VIIIa.

Heterozygous deficiency of plasma protein S predisposes to venous thrombosis. Heterozygous protein S deficiency is similar to heterozygous protein C deficiency in genetic transmission, prevalence, laboratory testing, treatment, and precautions.

Homozygous deficiency of protein S can cause neonatal purpura fulminans that is clinically indistinguishable from that caused by homozygous deficiency of protein C.

Acquired deficiencies of protein C (and, soon thereafter, protein S) occur during disseminated intravascular coagulation (DIC) and warfarin therapy.

Diagnosis is based on antigenic assays of total or free plasma protein S (free protein S is the form unbound to the protein S carrier molecule, C4-binding protein).

Treatment

  • Anticoagulation

The treatment of protein S deficiency associated with venous thrombosis is identical to the treatment of protein C deficiency, with one exception. Because there is no purified protein S concentrate available for transfusion, normal plasma is used to replace protein S during a thrombotic emergency.

It is not known if the newer oral anticoagulants that inhibit either thrombin (dabigatran) or factor Xa (eg, rivaroxaban, apixaban) can be used in place of other anticoagulants for this disorder.

Drugs Mentioned In This Article

  • Drug Name
    Select Trade
  • XARELTO
  • COUMADIN
  • ELIQUIS

* This is the Professional Version. *